A multi-center, double-blind, randomised, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of elderly patients with major depressive disorder.

Trial Profile

A multi-center, double-blind, randomised, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of elderly patients with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2013

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms SAPPHIRE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Jul 2013 Results published in the Journal of Affective Disorders.
    • 03 Dec 2011 Reults reported at the 11th International Forum on Mood and Anxiety Disorders.
    • 22 May 2010 Results have been presented at the 163rd Annual Meeting of the American Psychiatric Association (APA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top